BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15458277)

  • 1. Expression of c-erbB-2 and p53 in breast carcinoma patients: comparison with traditional prognostic factors and survival.
    Gurkan A; Erdogan G; Erdogan O; Pestereli E; Ogus M; Karaveli S; Colak T
    J Int Med Res; 2004; 32(5):455-64. PubMed ID: 15458277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C-erbB-2, p53, and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation.
    Bertheau P; Steinberg SM; Merino MJ
    Hum Pathol; 1998 Apr; 29(4):323-9. PubMed ID: 9563780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer.
    Nakopoulou LL; Alexiadou A; Theodoropoulos GE; Lazaris AC; Tzonou A; Keramopoulos A
    J Pathol; 1996 May; 179(1):31-8. PubMed ID: 8691341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
    Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
    J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-erbB-2 onco-protein expression in breast cancer: relationship to tumour characteristics and short-term survival in Universiti Kebansaan Malaysia Medical Centre.
    Sharifah NA; Lee BR; Clarence-Ko CH; Tan GC; Shiran MS; Naqiyah I; Rohaizak M; Fuad I; Tamil AM
    Asian Pac J Cancer Prev; 2008; 9(4):663-70. PubMed ID: 19271345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.
    Bebenek M; Bar JK; Harlozinska A; Sedlaczek P
    Anticancer Res; 1998; 18(1B):619-23. PubMed ID: 9568187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node--negative breast cancer: a tissue microarray study.
    Ko SS; Na YS; Yoon CS; Park JY; Kim HS; Hur MH; Lee HK; Chun YK; Kang SS; Park BW; Lee JH
    Int J Surg Pathol; 2007 Apr; 15(2):98-109. PubMed ID: 17478762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis.
    Rosen PP; Lesser ML; Arroyo CD; Cranor M; Borgen P; Norton L
    J Clin Oncol; 1995 Apr; 13(4):821-30. PubMed ID: 7707107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.
    Chen HH; Su WC; Guo HR; Chang TW; Lee WY
    Jpn J Clin Oncol; 2002 Sep; 32(9):332-9. PubMed ID: 12417598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis.
    Fernández Aceñero MJ; Farina González J; Arangoncillo Ballesteros P
    Gen Diagn Pathol; 1997 Jun; 142(5-6):289-96. PubMed ID: 9228251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prognostic value of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in node positive breast cancer patients treated by mastectomy].
    Wang SL; Li YX; Song YW; Wang WH; Jin J; Liu YP; Liu XF; Yu ZH
    Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):520-5. PubMed ID: 21029696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
    Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
    Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical characteristics and prognosis of breast cancer patients with vascular invasion].
    Zhao WH; Xu BH; Zhang P; Li Q; Zhao LM; Sun Y
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):137-40. PubMed ID: 17645853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.